Maintenance – Talk Bio

Actionable Insights Powered by AI

Eisai Anticipates Growth Acceleration for Alzheimer’s Drug Leqembi Despite Slow Initial Uptake

2 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Diagnostics, dosing, Eisai, expansion, Growth, Leqembi, Maintenance, Phase, Sales - occupational activity

Leqembi, Alzheimer’s disease, Eisai, expansion phase, sales growth, diagnostics, maintenance dosing, patient adoption

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

3 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

7 months ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

11 months ago talkbio0Tagged Disease remission, Effectiveness, guselkumab, Inflammatory Bowel Diseases, J&J, Johnson & Johnson, Maintenance, Phase 3 Clinical Trials, Safety, Tremfya, Ulcerative Colitis

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.